naturally selected cd7 car-t therapy without genetic manipulations for t-all/lbl
Published 2 years ago • 76 plays • Length 5:39Download video MP4
Download video MP3
Similar videos
-
3:07
the role of bridging and timing in car-t
-
1:06
car-t cell therapy: current applications and how to improve treatment strategies in the future
-
1:12
strategies to improve the quality of life of patients with mpns
-
2:17
the need to improve the quality of life of patients with aml undergoing allosct
-
4:12
opportunities to improve car-t outcomes
-
0:51
car-t as a frontline standard of care in all?
-
1:26
the impact of covid-19 on car-t therapy
-
1:02
the use of car-t cell products in a real-world setting
-
1:15
car-t therapy: where is it going?
-
1:23
moving car-t therapy to the outpatient setting
-
3:05
car-t therapy in r/r dlbcl
-
4:26
making an impact in all therapy: how can cure rates be improved?
-
1:06
how can we monitor a patient’s quality of life?
-
1:38
the future of car-t for hematological malignancies and solid tumors
-
2:44
car-t: driving the field
-
2:01
car-t activity in europe
-
4:49
hematopoietic recovery post-car-t
-
5:15
outlook on the current car-t climate
-
1:17
nk-car immunotherapy: the next steps